Government-Owned Inventions; Availability for Licensing, 68588-68590 [E7-23514]

Download as PDF 68588 Federal Register / Vol. 72, No. 233 / Wednesday, December 5, 2007 / Notices Estimated number of respondents Type of respondents Estimated number of responses per respondent * Average burden hours per response Estimated total annual burden hours requested 346 121 1.2 1.2 0.5 0.5 208 73 Total .................................................................................................. mstockstill on PROD1PC66 with NOTICES Participants .............................................................................................. Participant proxies ................................................................................... 467 1.2 0.5 281 Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Jean Olson, Epidemiology Branch, Division of Prevention and Population Sciences, NHLBI, NIH, II Rockledge Centre, 6701 Rockledge Drive, Suite 10018, MSC # 7936, Bethesda, MD 20892–7936, or call 301–435–0397 (non-toll-free number), or e-mail your request, including your address to: OlsonJ@nhlbi.nih.gov. Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication. VerDate Aug<31>2005 19:05 Dec 04, 2007 Jkt 214001 Dated: November 1, 2007. Mike Lauer, Director, Division of Prevention and Population Sciences, NHLBI, National Institutes of Health. Dated: November 20, 2007. Suzanne Freeman, OMB Clearance Officer, NHLBI, National Institutes of Health. [FR Doc. E7–23515 Filed 12–4–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. New Epitopes Recognized by Antibodies Against Human and Avian Influenza for Vaccines and Diagnostic Assays Description of Technology: Available for licensing and commercial development are intellectual properties drawn to peptides and polypeptides that elicit immunogenic responses in a PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 mammal; especially neutralizing antibodies, against human and avian influenza strains H1N1, H3N2, H5N1 and H7N7. Materials in the form of immunogenic compositions including these peptides and polypeptides can also be in-licensed along with the patent rights. Pharmaceutical compositions including these peptides and polypeptides with or without adjuvants are within the scope of the invention. Nucleic acids and expression cassettes encoding these peptides and polypeptides are also within the scope of the invention. Methods of inhibiting infection by influenza, with or without cell entry, are also within the scope of the invention using the aforementioned peptides and polypeptides. Applications: Vaccines; Therapeutics; Diagnostics; Influenza. Inventors: Hana Golding and Surender Khurana (FDA). Patent Status: U.S. Provisional Application No. 60/929,119 filed 13 June 2007 (HHS Reference No. E–236– 2007/0–US–01). Licensing Status: Available for licensing. Licensing Contact: Michael A. Shmilovich, Esq.; 301/435–5019; shmilovm@mail.nih.gov. Collaborative Research Opportunity: The FDA/CBER Laboratory of Retrovirus Research is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Beatrice A. Droke at 301/827– 7008 or bdroke@oc.fda.gov for more information. Trifunctional Imaging Agent for Monoclonal Antibody Tumor-Targeted Imaging Description of Technology: Available for licensing and commercial development is a novel lysine-based trifunctional chelate which bears both a chelating moiety (CHX–A″) for sequestering radiometals (86Y or 111In) and a near-infrared dye, e.g., Cy5.5, for dual modality PET (or SPECT) and fluorescence imaging. Successful conjugation of monoclonal antibody trastuzumab (Herceptin) or cetuximab (Erbitux) has also been achieved by efficient thiol-maleimide chemistry, E:\FR\FM\05DEN1.SGM 05DEN1 Federal Register / Vol. 72, No. 233 / Wednesday, December 5, 2007 / Notices Patent Status: U.S. Provisional Application No. 60/929,913 filed 17 Jul 2007 (HHS Reference No. E–194–2007/ 0–US–01). Licensing Status: Available for licensing. Licensing Contact: Michael A. Shmilovich, Esq.; 301/435–5019; shmilovm@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute Radiation Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, Trifunctional Imaging Agent for Monoclonal Antibody TumorTargeted Imaging. Please contact John D. Hewes, PhD at 301–435–3121 or hewesj@mail.nih.gov for more information. Applications: Imaging; Cancer; Multiple Sclerosis. Inventors: Martin W. Brechbiel (NCI), Peter L. Choyke (NCI), et al. Patent Status: U.S. Provisional Application No. 60/907,085 filed 19 Mar 2007 (HHS Reference No. E–157–2007/ 0–US–01 and HHS Reference No. E– 157–2007/1–US–01). Licensing Status: Available for licensing. VerDate Aug<31>2005 19:05 Dec 04, 2007 Jkt 214001 Nanoparticles for Imaging: Targeted Nanoparticles That Can Be Imaged Through Magnetic Resonance, Optical, and Radioisotope Imaging Description of Technology: Available for licensing and commercial PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 development are patent rights covering tri-imageable nanoparticles which have great potential for application in the laboratory and clinic for labeling at the cellular level, diagnostics, and drug delivery. The particle includes a silica encased ultrasmall superparamagnetic iron oxide (SPIONs) that can be detected using MRI. A fluorescent probe (e.g., Cy5.5) for optical imaging is embedded in the silica. The resulting particles are about 20–25nm in diameter. Target specific antibodies are attached to the surface of the particles. Chelated to the antibodies is a radioisotope (e.g., Indium–111) useful for particle quantification and can be imaged through techniques such as single photon emission computed tomography (SPECT) or positron emission tomography (PET). A graphical representation of an exemplary nanoparticle according to the invention is shown in the accompanying illustration. Licensing Contact: Michael A. Shmilovich, Esq.; 301–435–5019; shmilovm@mail.nih.gov. Collaborative Research Opportunity: The National Cancer Institute Radiation Oncology Branch is seeking statements E:\FR\FM\05DEN1.SGM 05DEN1 en05de07.013</GPH> mstockstill on PROD1PC66 with NOTICES thereby yielding an immunoconjugate (Signaling agent (Cy5.5–Lys(SMCC)– CHX–A″) conjugated to trastuzumab) or (Signaling agent (Cy7–Lys(SMCC)– CHX–A″) conjugated to cetuximab). Both specifically target antigen expressing cells and internalization of the agent has been imaged over time. Trastuzumab can be radiolabeled with isothiocyanate derivatives of the bifunctional chelating agents 1B4M (2– (4–aminobenzyl)–6– methyldiethylenetriaminepentaacetic acid); and CHX–A″ (N–[(R)–2–amino–3– (p-aminophenyl)propyl]-trans-(S,S)– cyclohexane–1,2–diamine– N,N,N′,N″,N″–pentaacetic acid). Applications: Imaging; Diagnostics. Inventors: Martin W. Brechbiel, Heng Xu, Kwamena E. Baidoo (NCI). Publication: H Xu et al. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. J Med Chem. 2007 Sep 20;50(19):4759–4765. 68589 68590 Federal Register / Vol. 72, No. 233 / Wednesday, December 5, 2007 / Notices conducted by the National Eye Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize these tri-imageable nanoparticles. Please contact John Hewes, PhD, at 301–435–3121 or hewesj@mail.nih.gov for more information. Dated: November 27, 2007. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E7–23514 Filed 12–4–07; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Center for Complementary & Alternative Medicine; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Center for Complementary and Alternative Medicine Special Emphasis Panel, December 7, 2007, 8 a.m. to December 7, 2007, 5 p.m., Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD, 20814 which was published in the Federal Register on November 13, 2007, 72FR63915. This meeting is being amended to change the format to a telephone conference and to change the date from December 7, 2007 to December 18, 2007. The meeting is closed to the public. Dated: November 27, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–5928 Filed 12–04–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health mstockstill on PROD1PC66 with NOTICES National Eye Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Board of Scientific Counselors, National Eye Institute. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects VerDate Aug<31>2005 19:05 Dec 04, 2007 Jkt 214001 Name of Committee: Board of Scientific Counselors, National Eye Institute. Date: December 9–11, 2007. Time: 7 p.m. to 1 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institutes of Health, Building 31, 31 Center Drive, Bethesda, MD 20892. Contact Person: Sheldon S. Miller, PhD, Scientific Director, National Institutes of Health, National Eye Institute, Bethesda, MD 20892, (301) 451–6763. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Information is also available on the Institute’s/Center’s home page: www.nei.nih.gov, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS) Dated: November 28, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–5927 Filed 12–4–07; 8:45 am] Special Emphasis Panel; Health and Healthcare Trajectories. Date: December 11, 2007. Time: 2 p.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6100 Executive Boulevard, 5B01, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Marita R. Hopmann, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health, and Human Development, 6100 Building, Room 5B01, Bethesda, MD 20892, (301) 435–6911, hopmannm@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS) Dated: November 27, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–5930 Filed 12–4–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health BILLING CODE 4140–01–M National Library of Medicine; Notice of Meeting DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The portions of the meeting devoted to the review and evaluation of journals for potential indexing by the National Library of Medicine will be closed to the public in accordance with the provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., as amended. Premature disclosure of the titles of the journals as potential titles to be indexed by the National Library of Medicine, the discussions, and the presence of individuals associated with these publications could significantly frustrate the review and evaluation of individual journals. National Institutes of Health National Institute of Child Health and Human Development; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\05DEN1.SGM 05DEN1

Agencies

[Federal Register Volume 72, Number 233 (Wednesday, December 5, 2007)]
[Notices]
[Pages 68588-68590]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-23514]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

New Epitopes Recognized by Antibodies Against Human and Avian Influenza 
for Vaccines and Diagnostic Assays

    Description of Technology: Available for licensing and commercial 
development are intellectual properties drawn to peptides and 
polypeptides that elicit immunogenic responses in a mammal; especially 
neutralizing antibodies, against human and avian influenza strains 
H1N1, H3N2, H5N1 and H7N7. Materials in the form of immunogenic 
compositions including these peptides and polypeptides can also be in-
licensed along with the patent rights. Pharmaceutical compositions 
including these peptides and polypeptides with or without adjuvants are 
within the scope of the invention. Nucleic acids and expression 
cassettes encoding these peptides and polypeptides are also within the 
scope of the invention. Methods of inhibiting infection by influenza, 
with or without cell entry, are also within the scope of the invention 
using the aforementioned peptides and polypeptides.
    Applications: Vaccines; Therapeutics; Diagnostics; Influenza.
    Inventors: Hana Golding and Surender Khurana (FDA).
    Patent Status: U.S. Provisional Application No. 60/929,119 filed 13 
June 2007 (HHS Reference No. E-236-2007/0-US-01).
    Licensing Status: Available for licensing.
    Licensing Contact: Michael A. Shmilovich, Esq.; 301/435-5019; 
shmilovm@mail.nih.gov.
    Collaborative Research Opportunity: The FDA/CBER Laboratory of 
Retrovirus Research is seeking statements of capability or interest 
from parties interested in collaborative research to further develop, 
evaluate, or commercialize this technology. Please contact Beatrice A. 
Droke at 301/827-7008 or bdroke@oc.fda.gov for more information.

Trifunctional Imaging Agent for Monoclonal Antibody Tumor-Targeted 
Imaging

    Description of Technology: Available for licensing and commercial 
development is a novel lysine-based trifunctional chelate which bears 
both a chelating moiety (CHX-A'') for sequestering radiometals (\86\Y 
or \111\In) and a near-infrared dye, e.g., Cy5.5, for dual modality PET 
(or SPECT) and fluorescence imaging. Successful conjugation of 
monoclonal antibody trastuzumab (Herceptin) or cetuximab (Erbitux) has 
also been achieved by efficient thiol-maleimide chemistry,

[[Page 68589]]

thereby yielding an immunoconjugate (Signaling agent (Cy5.5-Lys(SMCC)-
CHX-A'') conjugated to trastuzumab) or (Signaling agent (Cy7-Lys(SMCC)-
CHX-A'') conjugated to cetuximab). Both specifically target antigen 
expressing cells and internalization of the agent has been imaged over 
time. Trastuzumab can be radiolabeled with isothiocyanate derivatives 
of the bifunctional chelating agents 1B4M (2-(4-aminobenzyl)-6-
methyldiethylenetriaminepentaacetic acid); and CHX-A'' (N-[(R)-2-amino-
3-(p-aminophenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamine-
N,N,N',N'',N''-pentaacetic acid).
    Applications: Imaging; Diagnostics.
    Inventors: Martin W. Brechbiel, Heng Xu, Kwamena E. Baidoo (NCI).
    Publication: H Xu et al. Design, synthesis, and characterization of 
a dual modality positron emission tomography and fluorescence imaging 
agent for monoclonal antibody tumor-targeted imaging. J Med Chem. 2007 
Sep 20;50(19):4759-4765.
    Patent Status: U.S. Provisional Application No. 60/929,913 filed 17 
Jul 2007 (HHS Reference No. E-194-2007/0-US-01).
    Licensing Status: Available for licensing.
    Licensing Contact: Michael A. Shmilovich, Esq.; 301/435-5019; 
shmilovm@mail.nih.gov. 
    Collaborative Research Opportunity: The National Cancer Institute 
Radiation Oncology Branch is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, Trifunctional Imaging Agent for Monoclonal Antibody Tumor-
Targeted Imaging. Please contact John D. Hewes, PhD at 301-435-3121 or 
hewesj@mail.nih.gov for more information.

Nanoparticles for Imaging: Targeted Nanoparticles That Can Be Imaged 
Through Magnetic Resonance, Optical, and Radioisotope Imaging

    Description of Technology: Available for licensing and commercial 
development are patent rights covering tri-imageable nanoparticles 
which have great potential for application in the laboratory and clinic 
for labeling at the cellular level, diagnostics, and drug delivery. The 
particle includes a silica encased ultrasmall superparamagnetic iron 
oxide (SPIONs) that can be detected using MRI. A fluorescent probe 
(e.g., Cy5.5) for optical imaging is embedded in the silica. The 
resulting particles are about 20-25nm in diameter. Target specific 
antibodies are attached to the surface of the particles. Chelated to 
the antibodies is a radioisotope (e.g., Indium-111) useful for particle 
quantification and can be imaged through techniques such as single 
photon emission computed tomography (SPECT) or positron emission 
tomography (PET). A graphical representation of an exemplary 
nanoparticle according to the invention is shown in the accompanying 
illustration.
[GRAPHIC] [TIFF OMITTED] TN05DE07.013

    Applications: Imaging; Cancer; Multiple Sclerosis.
    Inventors: Martin W. Brechbiel (NCI), Peter L. Choyke (NCI), et al.
    Patent Status: U.S. Provisional Application No. 60/907,085 filed 19 
Mar 2007 (HHS Reference No. E-157-2007/0-US-01 and HHS Reference No. E-
157-2007/1-US-01).
    Licensing Status: Available for licensing.
    Licensing Contact: Michael A. Shmilovich, Esq.; 301-435-5019; 
shmilovm@mail.nih.gov. 
    Collaborative Research Opportunity: The National Cancer Institute 
Radiation Oncology Branch is seeking statements

[[Page 68590]]

of capability or interest from parties interested in collaborative 
research to further develop, evaluate, or commercialize these tri-
imageable nanoparticles. Please contact John Hewes, PhD, at 301-435-
3121 or hewesj@mail.nih.gov for more information.

    Dated: November 27, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E7-23514 Filed 12-4-07; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.